Onduo Shares Preliminary Real-World Data From 740 Patients in Journal of Diabetes Science and Technology – December 11, 2019

A1c decrease of 2.3% in participants with baseline A1c >9%; mean follow-up time of 4.2 months; 46% received CGM, 30% rural participants

Positive real-world data from 740 Onduo participants across 21 states was just published in the Journal of Diabetes Science and Technology. Participants with baseline A1c above 9% (n=124) saw a mean A1c reduction of 2.3% from a baseline of ~10.8% (p<0.001). Participants with baseline A1cs between 8%-9% and 7%-8% also saw statistically significant reductions in A1c of 0.7% and 0.2%, respectively (exact baselines not shared). In participants with initial A1c <7%, A1c was maintained (6.3% at baseline vs. 6.4% at follow-up). Mean follow-up time was ~ four months.

During the study period, about a quarter (26%) of participants had a telemedicine appointment with an endocrinologist and nearly half received CGM (46%; Dexcom G5 and G6). We would be curious to see CGM metrics, such as Time in Range, and a comparison between the group that received CGM and the group that didn’t (e.g., Did the two groups see different A1c reductions? What were the demographic and geographic makeups of both groups?, etc.). As a reminder, Onduo’s care model starts with the Virtual Diabetes Care app, a cell-connected BGM (Telcare), test strips, and a home A1c testing kit with health coaches providing educational support. CGMs from Dexcom (Dexcom is a preferred CGM partner) and second level education with a CDE can also be provided. Onduo also has endocrinologists licensed in 49 states, available for telemedicine consultations.

  • Onduo’s latest round of real-world data matches well with previously shared results. At ADA’s Real-World Data Symposium in 2018, we saw a poster (n=133) showing significant 1.3% A1c reduction in the cohort of patients with baseline A1c ≥8% (n=44). Members with baseline A1c between 6%-7.9% maintained their A1cs over the 80-180 day follow-up period. At DiabetesMine University 2018, we heard that participants with A1c >9% regularly saw A1c reductions of 2+%, though an average value was never actually shared. Notably, we also heard that those with high baseline A1c and used real-time CGM often saw 3+% reductions – we wonder if the same was true in this larger set of real-world data.


--by Albert Cai and Kelly Close